Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alofanib
- Development stage
- Phase 1
- Lead developer
- Russian Pharmaceutical Technologies
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Alofanib is a first-in-class, small-molecule, allosteric inhibitor of fibroblast growth factor receptor type 2 (FGFR2). It binds to the extracellular domain of FGFR2 and inhibits its activity, thereby blocking basic FGF/FGFR2-related signal transduction pathways. This results in inhibition of FGF-induced endothelial cell proliferation and migration as well as suppression of tumor cell proliferation in FGFR2-overexpressing cancers. Unlike other FGFR inhibitors that act intracellularly, alofanib targets the extracellular region, potentially overcoming resistance due to isoform variation or mutations. Alofanib is being developed primarily for antineoplastic and antiangiogenic indications, with clinical trials focused on metastatic gastric cancer[1][2][3][4][5][6][7][8].
- Other names
- 1612888-66-0
02
Targets
FGFR2 (Keratinocyte growth factor receptor)
Beyond the preview
Go deeper on alofanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alofanib.